05.05.25 -- Is Pharma Becoming Overly Reliant On Acquisitions?

On this episode of Business of Biotech, Brian Lortie, President and CEO of Uniquity Bio, shares how his "no jerk" policy shapes leadership and culture at the clinical-stage immunology startup. Host Ben Comer dives into Lortie's experience at GSK, Endo, and Onspira, and explores Uniquity’s formation, business model, and strategy with Blackstone Life Sciences backing. Listen now!

Integrating pregnant women into clinical trials through strategic partnerships, accessible trial locations, and robust informed consent processes is essential.

Join UCL experts in exploring how advanced perfusion techniques and stirred-tank bioreactors can enhance CAR-T cell manufacturing with improved yields, scale-up, and reduced costs.

By shifting from reactive problem-solving to proactive planning, predictive intelligence ensures clinical trials meet their enrollment goals more efficiently.

Patients are more empowered, making it essential to promote better adherence, improve medical benefits, and bolster market perception. See the technologies enabling this shift toward patient-centricity.

Artificial intelligence’s transformative impact promises more efficient, cost-effective, and successful clinical trials across the pharmaceutical landscape.

As hospitals and translational facilities explore implementation, they concurrently evaluate whether or not to manufacture the therapies onsite. Here is a guideline of how and when to get started.